Get the Stockscreener App
5.29
2.22%
-0.12
After Hours:
5.29
Design Therapeutics Inc stock is traded at $5.29, with a volume of 238.71K.
It is down -2.22% in the last 24 hours and up +31.59% over the past month.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.
See More
Previous Close:
$5.41
Open:
$5.35
24h Volume:
238.71K
Relative Volume:
2.13
Market Cap:
$301.26M
Revenue:
-
Net Income/Loss:
$-66.86M
P/E Ratio:
-4.4083
EPS:
-1.2
Net Cash Flow:
$-58.82M
1W Performance:
+10.44%
1M Performance:
+31.59%
6M Performance:
+13.03%
1Y Performance:
+7.52%
1-Day Range:
$5.04
$5.50
1-Week Range:
$4.68
$5.50
52-Week Range:
$2.60
$7.77
Design Therapeutics Inc Stock (DSGN) Company Profile
Name
Design Therapeutics Inc
Sector
Industry
Phone
858-293-4900
Address
6005 HIDDEN VALLEY ROAD, CARLSBAD
Compare DSGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DSGN
Design Therapeutics Inc
|
5.29 | 296.13M | 0 | -66.86M | -58.82M | -1.20 |
|
VRTX
Vertex Pharmaceuticals Inc
|
389.08 | 99.27B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
586.96 | 62.28B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.18 | 59.14B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
707.96 | 43.34B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
300.14 | 36.72B | 3.81B | -644.79M | -669.77M | -6.24 |
Design Therapeutics Inc Stock (DSGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-07-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Nov-14-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-15-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-15-23 | Downgrade | SVB Securities | Outperform → Market Perform |
| Aug-15-23 | Downgrade | Wedbush | Outperform → Neutral |
| May-04-23 | Upgrade | Goldman | Sell → Neutral |
| Jun-10-22 | Initiated | Wedbush | Outperform |
| May-02-22 | Initiated | RBC Capital Mkts | Outperform |
| Jan-19-22 | Initiated | Goldman | Sell |
| Apr-20-21 | Initiated | Goldman | Neutral |
| Apr-20-21 | Initiated | Piper Sandler | Overweight |
| Apr-20-21 | Initiated | SVB Leerink | Outperform |
View All
Design Therapeutics Inc Stock (DSGN) Latest News
Is Design Therapeutics Inc. stock ready for a breakoutWeekly Trade Recap & Free Community Consensus Stock Picks - Newser
Combining machine learning predictions for Design Therapeutics Inc.2025 Market Trends & Long-Term Growth Stock Strategies - Newser
Clinical-Stage Biotech Design Therapeutics to Share Updates at 2025 Cantor Healthcare Conference in NYC - Stock Titan
What momentum shifts mean for Design Therapeutics Inc.Weekly Market Summary & Low Drawdown Investment Ideas - Newser
Will Design Therapeutics Inc. continue its uptrendGold Moves & Risk Managed Investment Signals - Newser
Visual trend scoring systems applied to Design Therapeutics Inc.Weekly Profit Report & AI Powered Market Trend Analysis - Newser
How to use a screener to detect Design Therapeutics Inc. breakouts2025 Analyst Calls & Consistent Profit Trading Strategies - Newser
Historical volatility pattern of Design Therapeutics Inc. visualizedAnalyst Upgrade & Community Supported Trade Ideas - Newser
Will Design Therapeutics Inc. rebound enough to break evenTrade Risk Summary & Daily Stock Trend Watchlist - Newser
Risk vs reward if holding onto Design Therapeutics Inc.Trade Entry Report & Free Low Drawdown Momentum Trade Ideas - Newser
Using flow based indicators on Design Therapeutics Inc.2025 Investor Takeaways & Community Consensus Picks - Newser
Can a trend reversal in Design Therapeutics Inc. lead to recoveryQuarterly Risk Review & AI Optimized Trading Strategy Guides - Newser
Smart tools for monitoring Design Therapeutics Inc.’s price actionWeekly Gains Summary & Real-Time Volume Spike Alerts - Newser
Will Design Therapeutics Inc. stock recover after recent dropJuly 2025 Catalysts & Smart Allocation Stock Reports - Newser
Using data models to predict Design Therapeutics Inc. stock movementForecast Cut & Long-Term Growth Plans - Newser
What high frequency data says about Design Therapeutics Inc.Market Volume Report & Technical Analysis for Trade Confirmation - Newser
Can volume confirm reversal in Design Therapeutics Inc.Weekly Stock Recap & Accurate Entry/Exit Alerts - Newser
Can technical indicators confirm Design Therapeutics Inc.’s reversalRate Hike & AI Powered Buy and Sell Recommendations - Newser
Why Design Therapeutics Inc. is moving today2025 Market Sentiment & AI Optimized Trade Strategies - Newser
How to build a custom watchlist for Design Therapeutics Inc.2025 Retail Activity & Safe Entry Point Alerts - Newser
Design Therapeutics Inc. Moves Into Overbought Range Analysts CautiousJuly 2025 News Drivers & Community Verified Swing Trade Signals - beatles.ru
Design Therapeutics Inc.’s Beta Climbs After Market VolatilityJuly 2025 Review & Growth Focused Stock Pick Reports - newsyoung.net
Will a bounce in Design Therapeutics Inc. offer an exitWeekly Earnings Recap & Real-Time Stock Price Movement Reports - Newser
Backtesting results for Design Therapeutics Inc. trading strategiesBuy Signal & Precise Swing Trade Alerts - Newser
Design Therapeutics Sees Increased R&D Expenses Amid $36.8M Net Loss - AInvest
Design Therapeutics Reports Increased R&D Expenses Amid Net Loss - TipRanks
What technical models suggest about Design Therapeutics Inc.’s comebackJuly 2025 Sector Moves & Consistent Profit Trade Alerts - Newser
Price action breakdown for Design Therapeutics Inc.2025 Price Momentum & Risk Controlled Stock Alerts - Newser
Using Bollinger Bands to evaluate Design Therapeutics Inc.Quarterly Profit Summary & Smart Allocation Stock Reports - Newser
Watch for Trend Continuation in Design Therapeutics Inc. Next Week2025 Valuation Update & Accurate Intraday Trade Tips - thegnnews.com
Design Therapeutics Inc Stock (DSGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
8.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):